Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 17/20 | 1.00 |
| ▸ | MELK | Q14680 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17890326 | 1.00 | FLT3 (1.00) | FLT3MELKMEN1KMT2ATDP1 | |
| SCHEMBL17890169 | 0.93 | FLT3 (0.87) | FLT3MELKMEN1KMT2ATDP1 | |
| SCHEMBL17890172 | 0.93 | FLT3 (0.87) | FLT3MELKMEN1KMT2ATDP1 | |
| SCHEMBL17890322 | 0.90 | FLT3 (1.00) | FLT3MELK | |
| SCHEMBL17890320 | 0.90 | FLT3 (1.00) | FLT3MELK | |
| SCHEMBL17890199 | 0.90 | FLT3 (1.00) | FLT3MELK | |
| SCHEMBL17890201 | 0.90 | FLT3 (1.00) | FLT3MELK | |
| SCHEMBL17890129 | 0.89 | FLT3 (1.00) | FLT3MELK | |
| SCHEMBL17890126 | 0.89 | FLT3 (1.00) | FLT3MELK | |
| SCHEMBL17890242 | 0.88 | FLT3 (0.83) | FLT3MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951029-B2 | Styryl quinazoline derivatives as pharmaceutically active agents | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2018-04-24 | — | — | US | disclosed |
| US-9951029-B2 | Styryl quinazoline derivatives as pharmaceutically active agents | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2018-04-24 | — | — | US | disclosed |
| US-9951029-B2 | Styryl quinazoline derivatives as pharmaceutically active agents | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2018-04-24 | — | — | US | disclosed |
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2016-07-07 | — | — | US | disclosed |
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2016-07-07 | — | — | US | disclosed |
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | FLT3, BCR, STK3 | FLT3 1/4885MELK 151/4885MEN1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.